[1]魏凯敏,胡玲.转录因子GATA3在垂体腺瘤分类中的研究进展[J].国际内分泌代谢杂志,2023,43(02):113-116.[doi:10.3760/cma.j.cn121383-20211204-12009]
　Wei Kaimin,Hu Ling..Progress of transcription factor GATA3 in the classification of pituitary adenomas[J].International Journal of Endocrinology and Metabolism,2023,43(02):113-116.[doi:10.3760/cma.j.cn121383-20211204-12009]
点击复制

转录因子GATA3在垂体腺瘤分类中的研究进展 ()
分享到：

《国际内分泌代谢杂志》[ISSN:1673-4157/CN:12-1383/R]

卷:
43
期数:
2023年02期
页码:
113-116
栏目:
综述
出版日期:
2023-03-20

文章信息/Info

Title:
Progress of transcription factor GATA3 in the classification of pituitary adenomas
作者:
魏凯敏; 胡玲
山西医科大学第五临床医学院内分泌科,太原 030012
Author(s):
Wei Kaimin;  Hu Ling.
Department of Endocrinology, the Fifth Clinical College of Shanxi Medical University, Taiyuan 030012, China
关键词:
转录因子;  GATA3;  促性腺激素细胞腺瘤;  促甲状腺激素细胞腺瘤;  零细胞腺瘤
Keywords:
Transcription factor;  GATA3;  Gonadotropin adenoma;  Thyroid stimulating hormone adenoma;  Null cell adenoma
DOI:
10.3760/cma.j.cn121383-20211204-12009
摘要:
垂体腺瘤是一种常见的中枢神经系统肿瘤,其不同类型的侵袭性及复发率不同。2017年世界卫生组织发布的第4版垂体神经内分泌肿瘤分类中,转录因子被纳入垂体腺瘤的分类标准,2022年最新第5版分类仍沿用根据转录因子确定细胞谱系进行分类的原则,同时将零细胞腺瘤重新进行了定义。有学者认为目前诊断的零细胞腺瘤可能是由于检测方法的局限性所致。转录因子GATA3作为目前研究的热点标记物,在最新研究中被发现可能是促性腺激素细胞腺瘤和促甲状腺激素细胞腺瘤的特征因子,有助于垂体腺瘤精准的分类和预后判断。本文从垂体腺瘤的新分类、转录因子、转录因子GATA3与促性腺激素细胞腺瘤、促甲状腺激素细胞腺瘤和零细胞腺瘤的关系这几方面作一综述,旨在为临床工作中垂体腺瘤的进一步分类及科研提供参考。
Abstract:
Pituitary adenomas are common tumors in central nervous system with different invasiveness and recurrence rates. In the 4th edition of the classification of pituitary neuroendocrine tumor published by the World Health Organization in 2017, transcription factors were included in the classification criteria for pituitary adenomas, and the 2022 updated version 5 classification still follows the principle of classification based on the determination of cell lineages by transcription factors, while redefining null cell adenomas. Some scholars believe that the current diagnosis of null cell adenoma may be due to the limitations of detection methods. The transcription factor GATA3, a hot-spot marker in current research, has been found to be a possible signature factor in gonadotropin cell adenomas and thyroid stimulating hormone cell adenomas in recent studies, and it is helpful for accurate classification and prognosis judgement of pituitary adenoma. This article reviews the new classification of pituitary adenomas, transcription factors, and the relationship between transcription factor GATA3 and gonadotropin cell adenomas, thyroid stimulating hormone cell adenomas, and null cell adenomas, to provide reference for further classification and scientific research of pituitary adenoma in clinical work.

参考文献/References:

[1] Lopes MBS.The 2017 World Health Organization classification of tumors of the pituitary gland:a summary[J].Acta Neuropathol,2017,134(4):521-535.DOI:10.1007/s00401-017-1769-8.
[2] 李储忠,何艳姣,谢微嫣,等.2022年第五版WHO垂体肿瘤分类解读 [J].中华神经外科杂志,2022,38(5):442-445.DOI:10.3760/cma.j.cn112050-20220413-00200.
[3] Nishioka H,Inoshita N,Mete O,et al.The complementary role of transcription factors in the accurate diagnosis of clinically nonfunctioning pituitary adenomas[J].Endocr Pathol,2015,26(4):349-355.DOI:10.1007/s12022-015-9398-z.
[4] Guo W,Lee W,Lu Y,et al.Incidence and significance of GATA3 positivity in gallbladder adenocarcinoma[J].Hum Pathol,2020,106:39-44.DOI:10.1016/j.humpath.2020.09.012.
[5] Zaidan N,Ottersbach K.The multi-faceted role of GATA3 in developmental haematopoiesis[J].Open Biol,2018,8(11):180152.DOI:10.1098/rsob.180152.
[6] Ayyanar P,Mitra S,Purkait S.GATA3 expression in the solid cell nest of thyroid[J].Indian J Pathol Microbiol,2020,63(3):493-494.DOI:10.4103/IJPM.IJPM_651_19.
[7] Mete O,Kefeli M,Çlkan S,et al.GATA3 immunoreactivity expands the transcription factor profile of pituitary neuroendocrine tumors[J].Mod Pathol,2019,32(4):484-489.DOI:10.1038/s41379-018-0167-7.
[8] Turchini J,Sioson L,Clarkson A,et al.Utility of GATA-3 expression in the analysis of pituitary neuroendocrine tumour(PitNET)transcription factors[J].Endocr Pathol,2020,31(2):150-155.DOI:10.1007/s12022-020-09615-4.
[9] 韩建国,张春阳.鞍区显微解剖结构的特点[J].包头医学院学报,2013,29(2):134-136.DOI:10.16833/j.cnki.jbmc.2013.02.075.
[10] Lake MG,Krook LS,Cruz SV,et al.Pituitary adenomas:an overview[J].Am Fam Physician,2013,88(5):319-327.
[11] Melmed S.Pituitary-tumor endocrinopathies[J].N Engl J Med,2020,382(10):937-950.DOI:10.1056/NEJMra1810772.
[12] Han X,Geng X,Li Z,et al.The relationship between phospho-p38,matrix metalloproteinase 9,and major histocompatibility complex class I chain-related molecule a expression in pituitary adenomas demonstrates a new mechanism of pituitary adenoma immune escape[J].World Neurosurg,2019,123:e116-e124.DOI:10.1016/j.wneu.2018.11.077.
[13] Zhang S,Cui Y,Ma X,et al.Single-cell transcriptomics identifies divergent developmental lineage trajectories during human pituitary development[J].Nat Commun,2020,11(1):5275. DOI:10.1038/s41467-020-19012-4.
[14] Gangat M,Radovick S.Pituitary hypoplasia[J].Endocrinol Metab Clin North Am,2017,46(2):247-257.DOI:10.1016/j.ecl.2017.01.003.
[15] Joudrey EM,Lechniak D,Petrik J,et al.Expression of growth hormone and its transcription factor,Pit-1,in early bovine development[J].Mol Reprod Dev,2003,64(3):275-283.DOI:10.1002/mrd.10237.
[16] Pulichino AM,Vallette-Kasic S,Couture C,et al.Mutations du facteur de transcription TPIT et différenciation hypophysaire [TPIT mutations reveal a new model of pituitary differentiation and account for isolated ACTH deficiency][J].Med Sci(Paris),2004,20(11):1009-1013.DOI:10.1051/medsci/200420111009.
[17] Zhao L,Bakke M,Krimkevich Y,et al.Steroidogenic factor 1(SF1)is essential for pituitary gonadotrope function[J].Development,2001,128(2):147-154.DOI:10.1242/dev.128.2.147.
[18] Chou J,Provot S,Werb Z.GATA3 in development and cancer differentiation:cells GATA have it! [J].J Cell Physiol,2010,222(1):42-49.DOI:10.1002/jcp.21943.
[19] Pihlajoki M,Färkkilä A,Soini T,et al.GATA factors in endocrine neoplasia[J].Mol Cell Endocrinol,2016,421:2-17.DOI:10.1016/j.mce.2015.05.027.
[20] Lowry JA,Atchley WR.Molecular evolution of the GATA family of transcription factors:conservation within the DNA-binding domain[J].J Mol Evol,2000,50(2):103-115.DOI:10.1007/s002399910012.
[21] Ho IC,Vorhees P,Marin N,et al.Human GATA-3:a lineage-restricted transcription factor that regulates the expression of the T cell receptor alpha gene[J].EMBO J,1991,10(5):1187-1192.DOI:10.1002/j.1460-2075.1991.tb08059.x.
[22] Ko LJ,Yamamoto M,Leonard MW,et al.Murine and human T-lymphocyte GATA-3 factors mediate transcription through a cis-regulatory element within the human T-cell receptor delta gene enhancer[J].Mol Cell Biol,1991,11(5):2778-2784.DOI:10.1128/mcb.11.5.2778-2784.1991.
[23] Labastie MC,Bories D,Chabret C,et al.Structure and expression of the human GATA3 gene[J].Genomics,1994,21(1):1-6.DOI:10.1006/geno.1994.1217.
[24] Umeoka K,Sanno N,Osamura RY,et al.Expression of GATA-2 in human pituitary adenomas[J].Mod Pathol,2002,15(1):11-17.DOI:10.1038/modpathol.3880484.
[25] Micko A,Rötzer T,Hoftberger R,et al.Expression of additional transcription factors is of prognostic value for aggressive behavior of pituitary adenomas[J].J Neurosurg,2020,134(3):1139-1146.DOI:10.3171/2020.2.JNS2018.
[26] Nishioka H,Inoshita N,Mete O,et al.The complementary role of transcription factors in the accurate diagnosis of clinically nonfunctioning pituitary adenomas[J].Endocr Pathol,2015,26(4):349-355.DOI:10.1007/s12022-015-9398-z.
[27] Drummond J,Roncaroli F,Grossman AB,et al.Clinical and pathological aspects of silent pituitary adenomas[J].J Clin Endocrinol Metab,2019,104(7):2473-2489.DOI: 10.1210/jc.2018-00688.
[28] Manojlovic-Gacic E,Engström BE,Casar-Borota O.Histopathological classification of non-functioning pituitary neuroendocrine tumors[J].Pituitary,2018,21(2):119-129.DOI:10.1007/s11102-017-0855-1.
[29] Hickman RA,Bruce JN,Otten M,et al.Gonadotroph tumours with a low SF-1 labelling index are more likely to recur and are associated with enrichment of the PI3K-AKT pathway[J].Neuropathol Appl Neurobiol,2021,47(3):415-427.DOI:10.1111/nan.12675.
[30] Beck-Peccoz P,Brucker-Davis F,Persani L,et al.Thyrotropin-secreting pituitary tumors[J].Endocr Rev,1996,17(6):610-638.DOI:10.1210/edrv-17-6-610.
[31] Ónnestam L,Berinder K,Burman P,et al.National incidence and prevalence of TSH-secreting pituitary adenomas in Sweden[J].J Clin Endocrinol Metab,2013,98(2):626-635.DOI:10.1210/jc.2012-3362.
[32] 范晓静,臧丽,杜锦,等.对国内153例垂体促甲状腺素腺瘤临床报道的文献复习[J].中华内分泌代谢杂志,2018,34(8):660-666.DOI:10.3760/cma.j.issn.1000-6699.2018.08.007.
[33] Cossu G,Daniel RT,Pierzchala K,et al.Thyrotropin-secreting pituitary adenomas:a systematic review and meta-analysis of postoperative outcomes and management[J].Pituitary,2019,22(1):79-88.DOI:10.1007/s11102-018-0921-3.
[34] Balogun JA,Monsalves E,Juraschka K,et al.Null cell adenomas of the pituitary gland:an institutional review of their clinical imaging and behavioral characteristics[J].Endocr Pathol,2015,26(1):63-70.DOI:10.1007/s12022-014-9347-2.

备注/Memo

备注/Memo:
通信作者:胡玲,Email:13753177960@163.com
更新日期/Last Update: 2023-04-15